FBRX - Company ID 0001419041
The table below shows Forte Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $12.41M |
Forte Biosciences, Inc. reported annual revenue of $36.00K for fiscal year 2019. That is down 99.8% from $18.04M in fiscal 2018. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.41M |
| $10.62M |
| $8.30M |
| $7.63M |
| $4.22M |
| Operating income | -$70.66M | -$36.60M | -$32.49M | -$13.90M | -$21.49M | -$46.28M |
| Income tax | $1.04M | $0.00 | - | - | - | - |
| Net income | -$69.38M | -$35.48M | -$31.48M | -$13.88M | -$21.71M | -$46.49M |
| EPS (diluted) | -$4.71 | -$12.17 | -$24.92 | -$0.80 | -$1.55 | - |